Recursion(US:RXRX)2026-01-13 18:30Financial Status - Recursion had $755 million in cash at the end of 2025, projecting runway through the end of 2027[18] - The company anticipates a cash burn of less than $390 million in 2026[39] Pipeline and Platform - Recursion has approximately 5 wholly-owned programs in clinical development and around 15 in discovery[17] - The company's platform has generated over $500 million in upfront and milestone payments[17] - Recursion's supercomputer holds ~65PB of data, including 40PB of proprietary data[45] Partnerships - Sanofi has achieved 4 milestones using AI-designed molecules[27] - Roche and Genentech have delivered 6 AI-powered biology maps[27] - Potential Roche and Genentech and Sanofi milestones per small molecule program is >$300M[17] Clinical Program (REC-4881) - In a study, 75% of evaluable patients with FAP responded to REC-4881 with a 43% median reduction in polyp burden at Week 13[68] - At Week 25, 82% of evaluable patients responded to REC-4881, with 73% achieving durable ≥30% reductions and a 53% median polyp burden reduction[71] - Approximately 87% of untreated FAP patients experienced an annual increase in polyp burden, averaging a 60% increase annually[57, 62]